Entrada Therapeutics (TRDA) Stock Price, Quote, News & History | Benzinga

SPY776.62−0.19%QQQ741.50−0.61%BTC/USD83,393.54+2.03%DIA516.37−0.30%GLD381.07−0.28%TLT78.33+0.36%

Entrada Therapeutics Inc (TRDA) Stock Price, Quote, News & History

TRDANASDAQ

Trade with Public

Trade with Public

$5.21

-0.29-5.27%

Last update: Oct 13, 11:52 AM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$5.50

Close

-

Volume / Avg.

36.75K / 350.67K

Day Range

$5.21 - $5.21

52 Wk Range

5.15 - 16.45

Market Cap

$214.15M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

32

Short Interest

11.91%

Days to Cover

9.86

Recent Entrada Therapeutics, Inc. News

Alpha Buying: Follow the Money From NVIDIA and Merck

Wall Street loves a good upgrade, especially when the stock has already doubled and the analyst can explain why everyone should have owned it six months ago. One place I look for ideas is the investment portfolios of

Tim Melvin

This HubSpot Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday

Wall Street analysts changed outlook on top names. Check all changes on analyst ratings page. See what analysts think about HUBS stock.

Avi Kapoor

Dow Dips 350 Points; US Foods Posts Downbeat Earnings

Dow falls over 100 points, S&P 500 and NASDAQ also down. Tech sector up, energy stocks down. US Foods reports lower Q1 earnings and sales. Agilon Health, Aaon, and Rackspace Technology see gains while Entrada, Fastly, and enGene Therapeutics decline. Euro zone and Asian markets mixed.

Avi Kapoor

Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why

Entrada Therapeutics stock plunged after the Duchenne trial data missed investor expectations despite positive functional improvement signals.

Vandana Singh

This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-134.67M

Investing Cash Flow (TTM)

160.16M

Financing Cash Flow (TTM)

650.00K

Free Cash Flow (TTM)

-134.35M

Capital Expenditure (TTM)

323.00K

Net Change in Cash (TTM)

26.14M

Analyst Trends and Forecast

1

May

1

Jun

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$46.31M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

49.13

PB Ratio (TTM)

0.92

Earnings Yield % (TTM)

-71.87%

Earnings Yield % (FWD)

-56.81%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$5.99

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$99.28M

Debt to Equity

0.21

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-